Skip Navigation LinksHome > July 1, 2014 - Volume 66 - Issue 3 > Effects of Sustained Viral Response in Patients With HIV and...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000156
Clinical Science

Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis

Berenguer, Juan MD, PhD*,†; Zamora, Francisco X. MD‡,§; Carrero, Ana MD, PhD*,†; Von Wichmann, Miguel A. MD, PhD; Crespo, Manel MD, PhD; López-aldeguer, José MD, PhD#; Aldámiz-Echevarría, Teresa MD, PhD*,†; Montes, Marisa MD, PhD‡,§; Quereda, Carmen MD, PhD**; Téllez, María J. MD, PhD††; Galindo, María J. MD, PhD‡‡; Sanz, José MD§§; Santos, Ignacio MD, PhD‖‖; Guardiola, Josep M. MD, PhD¶¶; Esteban, Herminia SB##; Bellón, José M. BS*,†; González-García, Juan MD, PhD‡,§; for the GESIDA HIVHCV Cohort Study Group

Collapse Box


Objective: We assessed the effects of sustained viral response (SVR), after treating with interferon–ribavirin (IF-RB), on mortality, liver-related (LR) events (decompensation, hepatocellular carcinoma), HIV progression, and liver stiffness in HIV/hepatitis C virus (HCV)-coinfected patients with nonadvanced liver fibrosis.

Methods: From a cohort of HIV/HCV-coinfected patients treated with IF-RB, we selected those with baseline liver fibrosis stages F0, F1, or F2 according to METAVIR. The study started when IF-RB was stopped and ended at death or at the last follow-up visit.

Results: A total of 695 patients were included (HCV genotype 1 or 4, 431; F0, 77; F1, 290; and F2, 328), and 274 patients achieved SVR. After a median follow-up of 4.9 years, the adjusted hazard ratio (aHR) [95% confidence interval (CI)] of LR events or overall death, for patients with SVR taking the group of patients with no SVR as a reference was 0.217 (0.079 to 0.599) (P = 0.003) for the whole cohort with F0 to F2. For patients with F0, the aHR (95% CI) was 0.514 (0.040 to 6.593) (P = 0.609), for patients with F1, the aHR (95% CI) was 0.305 (0.053 to 1.762) (P = 0.185), and for patients with F2, it was 0.075 (0.009 to 0.662) (P = 0.020). We also found that, in comparison with no SVR, SVR was followed by less frequent HIV progression for the entire population (F0 to F2) and less frequent liver stiffness across all categories of fibrosis.

Conclusions: SVR in HIV/HCV-coinfected patients with moderate stages of liver fibrosis is associated with a reduction of mortality and LR events, and with a reduction of progression of HIV and liver fibrosis.

© 2014 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.